Efficacy of novel SARS-CoV2 vaccines in preventing SARS- CoV- 2 infection: a systematic review and meta-analysis

Oct 11, 2025BMC infectious diseases

How well new COVID-19 vaccines prevent infection: a combined review and analysis

AI simplified

mRNA Technology on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

Eighteen studies with 186,657 participants indicate an overall of novel SARS-CoV-2 vaccines of 70.5%.

Among participants, 3.0% were infected by SARS-CoV-2, with 2.8% in the treatment group and 3.4% in the placebo group.
The BNT162B2 vaccine showed 100% efficacy, while mRNA-1273 exhibited the lowest efficacy at 36.8%.
The of infection was 84% lower in the treatment group compared to the placebo group.
Vaccines have the potential to protect 771 out of 1000 individuals from SARS-CoV-2 infection.

AI simplified

BACKGROUND: Efficacious SARS-CoV-2 vaccines are urgently required to prevent the spread of the emerging and re-emerging SARS-CoV-2.

OBJECTIVE: Aim to assess the of novel SRAS-CoV-2 vaccines in preventing SARS-CoV-2 infection.

METHODS: All randomized placebo-controlled clinical trials eligible for this review were included. Scopus, PubMed, the Cochrane Library, and Google Scholar were searched. The risk of bias in the included studies was assessed using the modified Cochrane risk of bias tool 2 for RCTs. Result synthesis was performed using STATA software version 17.4. Forest plots, heterogeneity tests, meta-regression, sensitivity analysis, and publication bias were used to present the results.

RESULT: Eighteen studies comprising 186,657 participants who took the full dose of SARS-CoV-2 in an RCT were included. Of the participants, 110,768 (59.3%) were males and 111,619 (59.8%) were treatment groups. A total of 5665 (3.0%) participants were infected by SARS-CoV-2. Among the treatment groups, 3140 (2.8%) and 2525 (3.4%) from the placebo group were infected by SARS-CoV-2. The most efficient SARS-CoV-2 vaccine was BNT162B2, with 100% efficacy, whereas mRNA-1273 was the least efficient vaccine, with 36.8% efficacy. The overall efficacy of novel SRAS-CoV-2 vaccines was 70.5% (95% confidence interval (CI), 53.5 to 79.7). The of being infected was 84% lower in the treatment group compared to the placebo group. The novel SRAS-CoV-2 vaccines are efficient enough to protect 771 people out of 1000 from being infected by SARS-CoV-2.

DISCUSSION: Novel SARS-CoV-2 vaccines are efficacious inn preventing SARS-CoV-2 infection. However, their efficacy varies.

SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-025-11717-5.

Key numbers

70.5%

Overall Vaccine

of novel SARS-CoV-2 vaccines in preventing infection.

84%

Reduction

of being infected in the vs. placebo group.

771 of 1000

Protection Rate

Estimated number of people protected from SARS-CoV-2 infection.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text (PDF) ↗View full text (HTML) ↗

Efficacy of novel SARS-CoV2 vaccines in preventing SARS- CoV- 2 infection: a systematic review and meta-analysis

Abstract

Key numbers

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief

Abstract

Key numbers

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief